we just got approval for gardasil for males in china in the 9 to 26-year-old category.are in the middle of launching that. that's 200 million people, 200 million males in the demographic we think we can go after on top of the 120 million females still out there. china is still an opportunity. increasingly, we are looking to how we go beyond china, broadly and frankly beyond gardasil to the breadth of the portfolio we have. >> i do want to talk about glp-1. you are working on things that i know are someone who under promises, possibility of over deliver. you have ideas that are different in terms of making it so it's f it's that big of a drug, there's a lot of room. >> we have two areas we are focusing on in the glp-1 space. we have in phase development, a glp-1 for mash. this is an injectable peptide that we think is best in class in liver fat reduction. it brings with it weight loss characteristics similar to ozempic. that drug is something we think could be important. while the glp-1s have been important, they have not penetrated the way we think they could. we think